hydroxychloroquine has been researched along with Disease, Pulmonary in 22 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM)." | 9.27 | Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. ( Bagwe, S; Cui, Y; El-Chemaly, S; Goldberg, HJ; Henske, EP; Lamattina, AM; Moss, J; Rosas, IO; Taveira-Dasilva, A, 2018) |
| "We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM)." | 5.27 | Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. ( Bagwe, S; Cui, Y; El-Chemaly, S; Goldberg, HJ; Henske, EP; Lamattina, AM; Moss, J; Rosas, IO; Taveira-Dasilva, A, 2018) |
| "Diffuse alveolar hemorrhage is an uncommon and often fatal condition in children that is characterized by distinct histopathological etiologies." | 1.51 | Acute pulmonary embolism in a child with ANCA-negative Idiopathic Pulmonary Capillaritis. ( Asseri, AA; Daines, CL; Zeng, Y, 2019) |
| "The progression from DLE to systemic lupus erythematosus has been reported in up to 28% of patients." | 1.39 | Pulmonary hemorrhage in a patient initially presenting with discoid lupus. ( Jiménez-Encarnación, E; Vilá, S; Vilá-Rivera, K, 2013) |
| "Pulmonary hemorrhage is infrequently encountered in pediatrics." | 1.36 | Diffuse pulmonary hemorrhage as presenting syndrome of HIV disease. ( B Shah, V; Kumar, N; Prasad Goyal, J, 2010) |
| "Treatment with prednisolone and hydroxychloroquine followed by inhaled corticosteroids may improve survival in children with IPH." | 1.34 | Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children. ( Bhargava, S; Kabra, SK; Lodha, R; Satyavani, A; Walia, M, 2007) |
| "Pulmonary hemorrhage is a major life-threatening manifestation in children and adolescents with systemic lupus erythematosus, as well as in adults." | 1.32 | Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. ( Lindsley, CB; Samad, AS, 2003) |
| "Sensorineural hearing loss has previously been reported with hydroxychloroquine treatment, but this is the first report in a child and associated to idiopathic pulmonary haemosiderosis and has the characteristic of being unilateral." | 1.31 | Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. ( Coutinho, MB; Duarte, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Montero, F | 1 |
| Martínez-Barrio, J | 1 |
| Serrano-Benavente, B | 1 |
| González, T | 1 |
| Rivera, J | 1 |
| Molina Collada, J | 1 |
| Castrejón, I | 1 |
| Álvaro-Gracia, J | 1 |
| Patel, M | 1 |
| Gangemi, A | 1 |
| Marron, R | 1 |
| Chowdhury, J | 1 |
| Yousef, I | 1 |
| Zheng, M | 1 |
| Mills, N | 1 |
| Tragesser, L | 1 |
| Giurintano, J | 1 |
| Gupta, R | 1 |
| Gordon, M | 1 |
| Rali, P | 1 |
| D'Alonso, G | 1 |
| Fleece, D | 1 |
| Zhao, H | 1 |
| Patlakh, N | 1 |
| Criner, G | 1 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Lamattina, AM | 1 |
| Taveira-Dasilva, A | 1 |
| Goldberg, HJ | 1 |
| Bagwe, S | 1 |
| Cui, Y | 1 |
| Rosas, IO | 1 |
| Moss, J | 1 |
| Henske, EP | 1 |
| El-Chemaly, S | 1 |
| Pal, P | 1 |
| De, H | 1 |
| Giri, PP | 1 |
| Ganguly, N | 1 |
| Mandal, A | 1 |
| Asseri, AA | 1 |
| Zeng, Y | 1 |
| Daines, CL | 1 |
| Vilá-Rivera, K | 1 |
| Jiménez-Encarnación, E | 1 |
| Vilá, S | 1 |
| Yachoui, R | 1 |
| Sehgal, R | 1 |
| Amlani, B | 1 |
| Goldberg, JW | 1 |
| Prior-Español, Á | 1 |
| Martínez-Morillo, M | 1 |
| Riveros-Frutos, A | 1 |
| Olivé, A | 1 |
| Freitas, A | 1 |
| Senra, V | 1 |
| Marinho, A | 1 |
| Guedes, M | 1 |
| Rodrigues, K | 1 |
| Neves, FS | 1 |
| Stoeterau, KB | 1 |
| Werner Castro, GR | 1 |
| Nobre, LF | 1 |
| Zimmermann, AF | 1 |
| Pereira, IA | 1 |
| Rajagopala, S | 1 |
| Singh, N | 1 |
| Gupta, K | 1 |
| Gupta, D | 1 |
| García-Luzardo, Mdel R | 1 |
| Aguilar-Fernández, AJ | 1 |
| Cabrera-Roca, G | 1 |
| Prasad Goyal, J | 1 |
| B Shah, V | 1 |
| Kumar, N | 1 |
| Aceti, A | 1 |
| Sciutti, R | 1 |
| Bracci, PR | 1 |
| Bertelli, L | 1 |
| Melchionda, F | 1 |
| Cazzato, S | 1 |
| Samad, AS | 1 |
| Lindsley, CB | 1 |
| Al-Raqum, HA | 1 |
| Uppal, SS | 1 |
| Al-Mutairy, M | 1 |
| Kumari, R | 1 |
| Kabra, SK | 1 |
| Bhargava, S | 1 |
| Lodha, R | 1 |
| Satyavani, A | 1 |
| Walia, M | 1 |
| Saeed, MM | 1 |
| Woo, MS | 1 |
| MacLaughlin, EF | 1 |
| Margetis, MF | 1 |
| Keens, TG | 1 |
| Coutinho, MB | 1 |
| Duarte, I | 1 |
| Rockhold, L | 1 |
| Harisdangkul, V | 1 |
| Dugowson, CE | 1 |
| Gilliland, BC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus[NCT01687179] | Phase 1 | 14 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Primary endpoint of this study was safety. Safety was assessed based on the adverse events and serious adverse events that occurred in these patients when they were on this combination therapy. Percentage of adverse events in each system at a dose was calculated from the total adverse events at that dose. Subjects were closely monitored and adverse events were classified and graded according to the Common Terminology Criteria for Adverse Events, (CTCAE) Version 4.0." (NCT01687179)
Timeframe: 48 weeks
| Intervention | Percentage of adverse events (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac Disorders | Eye Disorders | GI Disorders | General Disorders, Administration site condistions | Immune System disorders | Infections and infestations | Injury, poisoning, procedural complications | Investigations | Metabolism and nutrition disorders | Musculoskeletal, connective tissue disorders | Nervous system disorders | Psychiatric disorders | Renal and urinary disorders | Reproductive system and breast disorder | Respiratory, thoracic, mediastinal disorders | Skin and Subcutaneous disorders | Vascular disorders | |
| Sirolimus and Hydroxychloroquine 200 mg | 2.27 | 0 | 18.18 | 18.18 | 0 | 15.91 | 0 | 6.82 | 0 | 0 | 4.55 | 0 | 0 | 6.82 | 2.27 | 25.0 | 0 |
| Sirolimus and Hydroxychloroquine 400 mg | 1.11 | 1.11 | 22.22 | 6.67 | 0.56 | 8.33 | 0.56 | 20 | 3.33 | 4.44 | 5.00 | 0.56 | 7.78 | 1.11 | 9.44 | 6.11 | 1.67 |
3 reviews available for hydroxychloroquine and Disease, Pulmonary
| Article | Year |
|---|---|
Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature.
Topics: Adrenal Cortex Hormones; Adult; Amyloidosis; Anti-Bacterial Agents; Antitubercular Agents; Biopsy; E | 2010 |
Idiopathic pulmonary haemosiderosis in a child with Down's syndrome: case report and review of the literature.
Topics: Child, Preschool; Down Syndrome; Female; Hemosiderosis; Hemosiderosis, Pulmonary; Humans; Hydroxychl | 2012 |
Management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyc | 1986 |
1 trial available for hydroxychloroquine and Disease, Pulmonary
| Article | Year |
|---|---|
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
Topics: Acetyl-CoA Carboxylase; Adult; Biomarkers; Correlation of Data; Drug Monitoring; Drug Therapy, Combi | 2018 |
18 other studies available for hydroxychloroquine and Disease, Pulmonary
| Article | Year |
|---|---|
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agen | 2020 |
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumat | 2020 |
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |
Early Initiation of Steroid-sparing Drugs in Idiopathic Pulmonary Hemosiderosis.
Topics: Azathioprine; Child; Hemosiderosis; Hemosiderosis, Pulmonary; Humans; Hydroxychloroquine; Immunosupp | 2019 |
Acute pulmonary embolism in a child with ANCA-negative Idiopathic Pulmonary Capillaritis.
Topics: Acute Disease; Antibodies, Antineutrophil Cytoplasmic; Capillaries; Chest Pain; Child; Female; Hemor | 2019 |
Pulmonary hemorrhage in a patient initially presenting with discoid lupus.
Topics: Adult; Anti-Bacterial Agents; Biopsy; Bronchopneumonia; Diagnostic Errors; Disease Progression; Dysp | 2013 |
Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Azath | 2015 |
[Recurrent diffuse alveolar hemorrhage in systemic lupus erytematosus treated with rituximab and immunoglobulins].
Topics: Cyclophosphamide; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxychloroquine; Immunoglobulins | 2015 |
Chronic alveolar haemorrhage in a paediatric patient: a diagnostic and treatment challenge.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biopsy; C | 2015 |
Pulmonary amyloidosis in Sjögren's syndrome: a rare diagnosis for nodular lung lesions.
Topics: Amyloid; Amyloidosis; Antirheumatic Agents; Azathioprine; Coloring Agents; Congo Red; Drug Therapy, | 2009 |
[Idiopathic pulmonary haemosiderosis in childhood: a good response to systemic steroids, inhaled hydroxychloroquine and budesonide].
Topics: Administration, Inhalation; Budesonide; Child; Glucocorticoids; Hemosiderosis; Hemosiderosis, Pulmon | 2010 |
Diffuse pulmonary hemorrhage as presenting syndrome of HIV disease.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Child, Prescho | 2010 |
Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.
Topics: Adolescent; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Hemorrhage; H | 2003 |
Shrinking lung syndrome as a presenting manifestation of systemic lupus erythematosus in a female Kuwaiti.
Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Female; Glucocorticoids; Humans; | 2006 |
Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Female; Glucocorticoids | 2007 |
Prognosis in pediatric idiopathic pulmonary hemosiderosis.
Topics: Adolescent; Child; Child, Preschool; Female; Glucocorticoids; Hemosiderosis; Humans; Hydroxychloroqu | 1999 |
Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis.
Topics: Acoustic Impedance Tests; Audiometry; Child; Female; Follow-Up Studies; Hearing Loss, Sensorineural; | 2002 |
Rheumatoid arthritis occurring with sickle cell anemia--treatment dilemma.
Topics: Anemia, Sickle Cell; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Lung Diseases; Middl | 1989 |